HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Yoo, M. H. Articles by Yoon, Y. H. Search for Related Content PubMed PubMed Citation Articles by Yoo, M. H. Articles by Yoon, Y. H.

Riluzole Inhibits VEGF-Induced Endothelial Cell Proliferation In Vitro and Hyperoxia-Induced Abnormal Vessel Formation In Vivo

¹From the Creative Research Initiative Center for the Study of Central Nervous System Zinc and the Department of Neurology, and the ²Department of Ophthalmology, University of Ulsan College of Medicine, Seoul, Korea.

PURPOSE. The present study examined the effects of riluzole, a Food and Drug Administration–approved drug for amyotrophic lateral sclerosis, on VEGF-stimulated endothelial cell proliferation in culture, and on neovascularization in a rat model of retinopathy of prematurity (ROP).

METHODS. Human umbilical vein endothelial cell and bovine retinal endothelial cell cultures were treated with VEGF to induce endothelial cell proliferation in the presence or absence of riluzole. Activation of PKC ßII was examined by quantifying its phosphorylated form on immunoblots. ROP was induced in 5-day-old rat pups by raising them in hyperoxic conditions for 7 days and in normoxic conditions for the next 5 days. Dextran fluorescence retinal angiography was used to quantitatively assess ROP.

RESULTS. Riluzole inhibited VEGF-stimulated PKC ßII activation and cell proliferation in bovine retinal endothelial cell and human umbilical vein endothelial cell cultures. In addition, systemic administration of riluzole substantially ameliorated abnormal new vessel formation in the rat ROP model.

CONCLUSIONS. The present results suggest that riluzole is a potent inhibitor of VEGF-induced endothelial cell proliferation both in vivo and in vitro. Since long-term use of riluzole has already been proven safe in humans, the present data indicate that clinical trials of riluzole for proliferative retinopathies should be implemented expeditiously.

This article has been cited by other articles:

				K. AKAMATSU, M.-A. SHIBATA, Y. ITO, Y. SOHMA, H. AZUMA, and Y. OTSUKI Riluzole Induces Apoptotic Cell Death in Human Prostate Cancer Cells via Endoplasmic Reticulum Stress Anticancer Res, June 1, 2009; 29(6): 2195 - 2204. [Abstract] [Full Text] [PDF]

				G. Bensimon, A. Ludolph, Y. Agid, M. Vidailhet, C. Payan, P. N. Leigh, and for the NNIPPS Study Group Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study Brain, January 1, 2009; 132(1): 156 - 171. [Abstract] [Full Text] [PDF]

				M.-H. Yoo, Y. H. Yoon, H. Chung, K. S. Cho, and J.-Y. Koh Insulin Increases Retinal Hemorrhage in Mild Oxygen-Induced Retinopathy in the Rat: Inhibition by Riluzole Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5671 - 5676. [Abstract] [Full Text] [PDF]